RxDoctor Payments Data

Stephen Verb, MD

Ophthalmology · Madison Heights, MINPI 1528266129

Payments from drug & device makers

$1,777in general payments, 2019–2025

Across 98 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$860
  • Alcon$621
  • Glaukos Corporation$144
  • Bausch & Lomb Americas Inc.$60
  • Aerie Pharmaceuticals, Inc.$38
  • Dompe US, Inc.$22
  • plus $32 from 3 others

What the payments were for

  • Food & beverage$1,777100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,777 in reported general payments places this provider in the 55th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$188,814
Medicare patients
470
Services billed
2,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost184$102,015
CombiganBrimonidine Tartrate/Timolol90$48,404
Latanoprost1,945$41,170
Alphagan PBrimonidine Tartrate31$21,172
Brimonidine Tartrate367$20,603
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol77$20,261
Prednisolone Acetate285$18,455
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat570$18,412
SimbrinzaBrinzolamide/Brimonidine Tart53$18,174
Travoprost76$14,159
Cyclosporine13$10,355
Methazolamide15$8,634
RhopressaNetarsudil Mesylate13$8,596
Dorzolamide Hcl121$4,425
Timolol Maleate272$4,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$860$171,591305 claims
AlconSimbrinza$621$18,17453 claims
Aerie Pharmaceuticals, Inc.Rhopressa$38$8,59613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Madison Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →